Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

  • 11/20/2018 – Jazz Pharmaceuticals had its price target lowered by analysts at Mizuho to $157.00. They now have a “neutral” rating on the stock.
  • 11/14/2018 – Jazz Pharmaceuticals had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $161.00 price target on the stock.
  • 11/13/2018 – Jazz Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/13/2018 – Jazz Pharmaceuticals had its “hold” rating reaffirmed by analysts at Zacks Investment Research. According to Zacks, “After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in the first half. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for its leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Meanwhile, its newest drug Vyxeos performed below expectations and Jazz lowered its full-year outlook. Earnings estimates have gone down ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 11/8/2018 – Jazz Pharmaceuticals had its price target lowered by analysts at B. Riley from $219.00 to $190.00. They now have a “buy” rating on the stock.
  • 11/7/2018 – Jazz Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/7/2018 – Jazz Pharmaceuticals was given a new $200.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 11/7/2018 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/7/2018 – Jazz Pharmaceuticals was given a new $184.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 11/7/2018 – Jazz Pharmaceuticals was given a new $208.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 11/6/2018 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $201.00 price target on the stock. They wrote, “: We reiterate our Overweight rating and we are lowering our PT by $2 to $201 for JAZZ stock. We continue to believe management has positioned the company well for a solid financial performance in a post-Xyrem” world through innovation and diversification. We believe NT stock performance will be driven by potential FDA approval of solriamfetol and JZP-258 data in narcolepsy.””
  • 10/19/2018 – Jazz Pharmaceuticals was given a new $213.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 10/15/2018 – Jazz Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $173.00 price target on the stock.
  • 9/28/2018 – Jazz Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

NASDAQ:JAZZ traded up $2.44 during trading hours on Tuesday, hitting $145.63. 869,890 shares of the company’s stock traded hands, compared to its average volume of 509,916. The firm has a market capitalization of $8.61 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.79 and a beta of 1.06. Jazz Pharmaceuticals PLC has a twelve month low of $130.15 and a twelve month high of $184.00. The company has a current ratio of 4.29, a quick ratio of 4.16 and a debt-to-equity ratio of 0.52.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating the consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million for the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. Jazz Pharmaceuticals’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the firm earned $3.22 earnings per share. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 11.6 earnings per share for the current year.

In related news, CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction on Friday, September 21st. The stock was sold at an average price of $164.36, for a total transaction of $213,668.00. Following the transaction, the chief executive officer now directly owns 281,215 shares of the company’s stock, valued at $46,220,497.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Seamus Mulligan purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The shares were acquired at an average cost of $144.56 per share, for a total transaction of $7,228,000.00. The disclosure for this purchase can be found here. Insiders have sold 16,030 shares of company stock worth $2,668,011 over the last three months. 3.90% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the business. Stratos Wealth Partners LTD. acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $106,000. Riverhead Capital Management LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $113,000. Financial Enhancement Group LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $140,000. Tiverton Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $198,000. Finally, Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $204,000. 92.30% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Earnings Per Share

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.